How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market
- By Imaging Modality: Ultrasound Imaging Systems, Magnetic Resonance Imaging (MRI) Systems, Computed Tomography (CT) Scanners, Nuclear Medicine Imaging Systems, Elastography Devices
- By End-User: Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Research Institutes, Ambulatory Surgical Centers
- By Technology: 3D Imaging Systems, 2D Imaging Systems, Contrast-Enhanced Imaging, Portable Imaging Devices, High-Resolution Imaging Systems
- By Application: Liver Function Assessment, Bile Duct Visualization, Fibrosis Detection, Cholestasis Monitoring, Preoperative Imaging
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Ultrasound Imaging Systems leads By Imaging Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 12 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 12 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 12 company profiles, forecast to 2033.
Segmentation covered
Imaging Modality 5
End-User 5
Technology 5
Application 5
Companies profiled
Allengers
Canon
Carestream Health
CURA Healthcare
FUJIFILM
GE Healthcare
Hitachi Ltd.
Hologic Inc.
Koninklijke Philips N.V.
Neusoft Corporation
Siemens Healthineers
Shimadzu Corporation
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
12 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Allengers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Canon
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Carestream Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →CURA Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →FUJIFILM
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GE Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Hitachi Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hologic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Koninklijke Philips N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Neusoft Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Siemens Healthineers
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Shimadzu Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,492M by 2033 · 9.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Ultrasound Imaging Systems44.3
- Magnetic Resonance Imaging (MRI) Systems8.9
- Computed Tomography (CT) Scanners17.5
- Nuclear Medicine Imaging Systems16.9
- Elastography Devices12.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$389.8M → $870.6M · 10.6%
Europe$271.7M → $599.7M · 10.4%
Asia Pacific$248.1M → $520.1M · 9.7%
Latin America$153.6M → $307.6M · 9.1%
Middle East and Africa$118.1M → $235.6M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.742026
9.742027
9.752028
9.762029
9.782030
9.792031
9.802032
9.822033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Allengers22.5
- Canon16.5
- Carestream Health7.7
- CURA Healthcare3.6
- FUJIFILM11.4
- GE Healthcare10.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Imaging Modality31.5%
End-User30.4%
Technology19.7%
Application18.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.4
- Europe23.7
- Asia Pacific20.5
- Latin America12.1
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Allengers | 78 | 85 | 84 | 83 | 84 | 91 | 84 |
| Canon | 85 | 89 | 74 | 81 | 68 | 89 | 81 |
| Carestream Health | 87 | 76 | 84 | 88 | 77 | 84 | 83 |
| CURA Healthcare | 79 | 61 | 74 | 78 | 59 | 67 | 70 |
| FUJIFILM | 55 | 51 | 58 | 52 | 56 | 76 | 58 |
| GE Healthcare | 69 | 52 | 62 | 54 | 66 | 48 | 59 |
| Hitachi Ltd. | 43 | 51 | 54 | 62 | 58 | 62 | 55 |
| Hologic Inc. | 44 | 37 | 46 | 59 | 52 | 43 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Allengers
- Canon
- Carestream Health
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Allengers | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Canon | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Carestream Health | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| CURA Healthcare | ✓ | − | ◐ | ◐ | − | − |
| FUJIFILM | ◐ | − | ◐ | − | ◐ | ◐ |
| GE Healthcare | − | ◐ | ◐ | − | ◐ | ◐ |
| Hitachi Ltd. | − | − | ◐ | ✓ | − | − |
| Hologic Inc. | ◐ | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Allengers84
2Carestream Health83
3Canon81
4CURA Healthcare70
5GE Healthcare59
6FUJIFILM58
7Hitachi Ltd.55
8Hologic Inc.47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
AllengersCanonCarestream Health
Challenger1
Strong scale, closing on the leaders.
CURA Healthcare
Contender2
Focused players with pockets of strength.
FUJIFILMGE Healthcare
Niche2
Specialists in a single segment or region.
Hitachi Ltd.Hologic Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Imaging Modality in North America, then scale across Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market — a $451M beachhead inside a $6.87B market.
Beachhead (SOM)$451Mobtainable near-term
Serviceable (SAM)$2.48Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Ultrasound Imaging Systems
Best fit — highest urgency & budget in Imaging Modality.
Economic buyer75 fit
Magnetic Resonance Imaging (MRI) Systems
Strong fit — clear ROI and a fast path to value.
End user68 fit
Computed Tomography (CT) Scanners
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Imaging Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End-User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Imaging Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified24%
Evaluation13%
Closed-won5%
$21.2KCAC
$105KLTV
4.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market is a durable-growth opportunity — $4.02B by 2033, compounding at 6.1%.
TAM · 2025$2.50Btoday
TAM · 2033$4.02Bforecast
CAGR6.1%2027–2033
Cumulative$28.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.02BTotal addressable market
SAM$1.40BServiceable available market
SOM$260MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.1% CAGR
Demand compounds through 2033, outpacing GDP across Imaging Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Imaging Modality moving from early to mainstream — durable secular demand.
Consolidation upside
12+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.02BLarge & growingTAM by 2033 at 6.1% CAGR
$1.40BServiceable nowreachable with today’s model
$260MBeachhead winobtainable near-term share
12+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.13BBear4.0% CAGR
$4.02BBase6.1% CAGR
$5.14BBull8.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End-User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market — a $4.97B market by 2033. Plan: grow share from 9.7% to 17.2%.
Market size · 2033$4.97Btotal addressable
Market CAGR6.5%2027–2033
Target share17.2%from 9.7% today
Revenue ambition$855Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.7% | 17.2% | On track |
| Revenue | $467M | $855M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.1% | 38.4% | On track |
| Customer retention | 91.8% | 96.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Imaging Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End-User capability
A defensible second engine — invest in End-User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Imaging Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End-User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in End-User
- Authorise North America expansion plan
- Fund R&D program for Imaging Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market conversation — a $1.98B market you can size, segment and defend in minutes.
Market size · 2033$1.98Btotal opportunity
Growth4.2%CAGR to 2033
Addressable buyers1,568+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Imaging Modality
Goal Grow share in Imaging Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 3 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
12+players profiled in this market
Coverage includes
AllengersCanonCarestream HealthCURA HealthcareFUJIFILMGE HealthcareHitachi Ltd.Hologic Inc.+4 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Benign Recurrent Intrahepatic Cholestasis (BRIC) Diagnostic Imaging Equipment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Transcatheter Devices Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportWrist-worn Pulse Oximetry Devices Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportWidefield Imaging Device Market
Market size, share, segmentation and regional forecast.
$433M market · 2025 base year
View reportAmantadine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportWidefield Digital Imaging System Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportAutomatic Ventilators Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAutomatic Syringes Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportAppendicitis Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportAppendiceal Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportAmalgam UV Germicidal Lamp Market
Market size, share, segmentation and regional forecast.
$386M market · 2025 base year
View reportAPAP Machines Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportAmalgam Separators for Dentists Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.